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Background. To determine the efficacy of a new typhoid conjugate vaccine in an endemic setting in sub-Saharan Africa, the 
Typhoid Vaccine Acceleration Consortium is conducting a phase-3 randomized controlled trial in Blantyre, Malawi. This article 
describes community and stakeholder engagement activities before and during the trial, challenges, and lessons learned.
Methods. In October 2017, Malawi-Liverpool Wellcome Trust (MLW) organized a wide range of community engagement activ-
ities, including meetings with Ministry of Health and Education officials at the district and facility level, local community leadership, 
and parent teacher association groups. We engaged media outlets to include local and international television, radio, and print 
media. Community members were informed directly through a study jingle played via loudspeaker from a van and by communi-
ty-based activities.
To review engagement activity effectiveness: The MLW team met to discuss progress and challenges; and a focus group discussion 
(FGD), consisting of trial staff, sought feedback from the community on each engagement modality.
Results. The school-based vaccine campaign increased community participation exceeding recruitment targets to date (on aver-
age, >200 children/day).
Conclusions. The FGD concluded that the van and local activities improved awareness and turnout for the trial, but prior 
engagement with local government and community leadership is an essential mechanism to provide details of the study, answer 
questions, communicate the value of the study, and address safety concerns. Effective community engagement is essential in a large 
intervention trial. Multiple channels of communication are required to reach the community and deliver information needed for 
participation and provide opportunity for dialogue with the trial team.
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Typhoid fever is a major cause of febrile illness in many low- 
and middle-income countries, responsible for an estimated 12 
million infections globally each year and over 128 000 deaths 
[1–4]. Disease burden is borne mainly by infants and school-
age children [5]. Cases increased markedly throughout east 
and southern Africa after a new multidrug-resistant (MDR) 
strain appeared [6–8]. Although disease rates decreased in 
developed countries with improvements in water and sanita-
tion, the threat of escalating antimicrobial resistance (AMR) 
could reverse these trends [9, 10]. Therefore, prequalification 
of a new typhoid conjugate vaccine (Vi-TCV), Typbar-TCV®, 
by the World Health Organization (WHO) [11] after promising 
efficacy results from the Oxford human challenge model [12] 
is an encouraging development, meaning control of the global 
typhoid burden may be possible through vaccination.
After WHO prequalification of Typbar-TCV®, the WHO 
Strategic Advisory Group of Experts on Immunization recom-
mended Vi-TCV in countries with elevated burden of disease or 
increased rates of AMR [13]. Through funding from the Bill & 
Melinda Gates Foundation, the Typhoid Vaccine Acceleration 
Consortium (TyVAC) was formed to accelerate introduction 
of typhoid conjugate vaccines (TCVs) into low- and mid-
dle-income countries [14, 15] and provide evidence for vaccine 
impact through a series of efficacy trials in endemic countries.
Blantyre, Malawi has documented increased typhoid cases 
isolated from the central tertiary care hospital after a new MDR 
strain emerged [6, 8, 16]. The Strategic Typhoid Alliance across 
Africa and Asia (STRATAA), a collaboration between the 
University of Oxford, the Malawi-Liverpool Wellcome Trust 
(MLW), and other partners has further characterized elevated 
disease incidence using community-based typhoid epidemiol-
ogy surveillance in Ndirande township, Blantyre [17].
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The TyVAC Malawi trial is a phase-3 randomized, double 
blind, controlled trial of the clinical efficacy of TCV in 28 000 
children aged 9 months through 12 years. Children are random-
ized 1:1 to receive Vi-TCV or a meningitis A conjugate vaccine. 
TyVAC Malawi will follow participants, through passive surveil-
lance for febrile illness, up to 3 years. The primary outcome is 
blood culture-confirmed Salmonella Typhi (S. Typhi) infection.
Community stakeholder engagement is increasingly recog-
nized as essential for both ethical research practice and trial 
feasibility. Engagement can build trust with communities, gen-
erate awareness and understanding of the research, promote 
ownership among local stakeholders, and seek feedback that 
helps researchers ensure trial procedures are appropriate in 
the local setting. Engagement thus has the potential to reduce 
exploitation and harm, support recruitment [18–20], facili-
tate research activities and enable the feedback of findings to 
the population; however, community engagement is a complex 
undertaking, and there are few published examples to provide 
lessons for future practice. Previous research in Malawi has 
described varied community perceptions of vaccine trials [21], 
the importance of community engagement [22], and challenges 
surrounding engagement strategies [23]. This article describes 
the largest community and stakeholder engagement effort 
undertaken by MLW and draws on reflections from trial staff to 
evaluate the relative success of different engagement modalities.
METHODS
Setting
In October 2017, approximately 5 months before the first vacci-
nation, MLW conducted a range of engagement activities within 
the communities of Ndirande and Zingwangwa townships 
(Figure 1). Both townships are densely populated urban cen-
ters with a combined population of roughly 200 000 people. For 
sub-Saharan Africa, they are a typically youthful population [24] 
with increased rates of in-migration as people relocate from vil-
lages for economic and educational opportunities. Vaccination 
administration occurred at 2 health centers and multiple pri-
mary schools throughout the community (Figure 2).
Community Engagement Activities
 • Community engagement taskforce
Under the guidance and leadership of the Blantyre district 
health office (DHO), the taskforce consisted of education offi-
cers, school health and nutrition officers, extended programme 
immunization (EPI) officers, health promotion officers, the 
chief nursing officer, members of the Malawi TyVAC team, 
and DHO administration. The taskforce designed and imple-
mented engagement activities for trial initiation. The DHO 
provided district-level permission to perform the study and 
January 2018
Community meeting;
• Chiefs
• Religious leaders
• Community Based
Organisations
• Business representatives
• Women’s groups
December 2017
Study protocol shared;
• Ministry of Health
• Ministry of Education
October 2017
Taskforce engagement committee
• Education officers
• EPI co-ordiantor
• Health promotion officer
• Chief nursing officer
• DHO administration
• MLW staff
January – February 2018
22 Individual school meetings;
• PEAs
• Teachers
• PTA
• SMC
• Women’s groups
January 2018
Community health committee
meetings;
• HSAs
• VHCs
February – September 2018
• Mobile Van with audio recording
informing people and inviting them
to vaccine clinic
November 2017
Community representative
meetings;
• Community advisors from
Blantyre and Ndirande
consulted on
engagement plan and
study activity
Figure 1. Timeline of engagement activities. Abbreviations: DHO, District Health Officer; EPI, extended programme of immunization; HSA, health surveillance assistants; 
MLW, Malawi Liverpool Wellcome Trust; PEA, primary education advisors; PTA, parent teacher association; SMC, school management committee; VHC, village health 
committee.
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to use designated health and educational facilities for study 
activities. This permission and support were essential to gain 
facility access and be seen as a legitimate activity by the commu-
nity. The taskforce involved 20 people and cost approximately 
$275 USD.
 • Community advisory group (CAG) meetings
MLW’s resident group of about 20 community advisors consult 
on study conduct in and around Blantyre. The TyVAC team 
explained the trial and engagement plan and sought feedback.
 • Ministry of Health and Ministry of Education (MoH/MoE)
The MoH and MoE has to grant permission for study 
implementation in Blantyre. The Malawi TyVAC trial team 
provided study protocols to the ministries, answered ques-
tions, and clarified planned activities. Once permission was 
obtained from MoH, management and clinic staff in individ-
ual health facilities were trained on the protocol through col-
laboration with the DHO. Similarly, permission was sought 
from MoE. Because this was the first time that schools were 
used for a large-scale medical research trial in Malawi, and 
because the MoE is less connected with the national research 
ethics regulatory bodies, TyVAC Malawi obtained face-to-
face permission from the Minister and Permanent Secretary 
for Education prior to regional and local engagement. 
Subsequent contact with individual schools was mediated 
by the School Health and Nutrition Officer, who acted as 
the key link between health and education departments. The 
support of these 2 ministries was vital for individual school 
engagement. Study information was disseminated at each 
school via presentations, discussion groups, flyers, posters, 
and letters home.
 • Community leaders meetings in Ndirande and Zingwangwa
Over 2 days, TyVAC Malawi brought together traditional village 
chiefs and headman, ward councillors, religious leaders, busi-
ness representatives, women’s groups, and community-based 
organizations to explain the study and answer questions. 
Approximately 160 community leaders were engaged in this 
process, costing $840 USD.
 • School-based meetings
The engagement taskforce visited 22 schools to present a study 
overview and seek participation to establish vaccine clinics on 
school property. The individual meetings involved primary 
education advisors, teachers, parent-teacher association, school 
management committee members, and women’s groups. The 
taskforce sought permission to recruit within the school, pro-
vided clarification, and responded to questions from partici-
pants. The schools became the primary location of vaccination 
for both school aged children and nonschool aged children as 
mothers often brought multiple children for vaccination. Over 
200 people participated in these meetings costing approxi-
mately $8250 USD.
Figure 2. Blantyre city with Ndirande (upper middle), Zingwangwa (lower middle), and Nancholi (lower left) townships with schools (yellow), and health centers(red) 
located. Source: Google Earth.
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 • Community health committee meetings
Health surveillance assistants (HSAs) and village health com-
mittees are vital members of the primary health care system 
in Malawi. These individuals are responsible for immuniza-
tions, conducting household follow-up, and distributing health 
messages to the local community. Engagement with this group 
focused on their assistance disseminating study information 
and relaying questions and feedback from the community to the 
study team. Time was spent ensuring HSAs understood the study 
protocol, eligibility criteria, and key messages. Approximately 50 
people were involved in these meetings at a cost of $1375 USD.
 • Mobile van with invitation to come for vaccination
A local musician created a jingle containing study messages and 
invited guardians to bring children for vaccination. This jingle 
played via a mobile van with large speakers on the roof that drove 
through the communities. The van operated in the early evening 
when parents were home and before nighttime when vehicle secu-
rity became problematic. The van campaign began 2 weeks before 
first vaccinations and continued throughout the vaccination period. 
Production costs and van use totaled approximately $1925 USD.
 • Assessment methods
To obtain preliminary feedback on the benefits and challenges of 
different engagement activities, we held reflection meetings with 
trial and engagement staff throughout the vaccine campaign. To 
generate additional feedback, we held a focus discussion group 
with frontline trial staff to better understand community reac-
tions and recruitment challenges. Frontline staff bring particular 
insight to discussions of community engagement and research 
ethics because of direct contact with community members and 
participants [25]. The focus group included 6 frontline trial 
staff (including fieldworkers and research nurses responsible for 
approaching community members, meeting community mem-
bers at trial sites, taking consent, and facilitating vaccination). To 
support open discussion, a nontrial team member facilitated the 
1-hour focus group. All participating staff provided verbal con-
sent to use focus group material within this article.
RESULTS
Community engagement was a benefit to the trial and encour-
aged community uptake in a number of ways:
 1. Providing feedback that helped design engagement activities 
and consent procedures
Discussions with the CAG and other stakeholders helped the 
trial team identify appropriate ways to engage the Blantyre 
community and select specific activities.
 2. Creating awareness and increasing recruitment
Initial consultation with the CAG highlighted areas to focus. 
A member advised:
“The use of a mobile van with key messages would be 
effective in recruitment for the study. This is still a pop-
ular medium by which health, political, and commercial 
messages are delivered to mass audiences in Blantyre and 
TyVAC should take advantage of this.”
The mobile van increased recruitment success (Figure 3) and as 
noted by a frontline trial team member:
“The van is best. Mostly they do it at night when everyone 
is almost home, and it was very effective. Almost everyone 
got the information. Everyone was saying ‘during the night 
they were saying this, they were saying this, we have to go 
there.’ When the van has gone around, we do have good 
turn up.”
The community engagement resulted in a cartoon appearing in 
a major newspaper. The appearance of this cartoon, unsolicited 
and entirely unrelated to the public engagement teams, indi-
cated engagement penetration with the general public. When 
the cartoonist was contacted, he confirmed that the study van 
campaign and other engagement efforts prompted him to write 
the cartoon (Figure 4).
 3. Opportunity to provide information and answer questions
Figure 3. Vaccine recruitment by month. Van sensitization events are shown as 
bars.
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Although the van increased awareness of the study, which 
helped recruitment, other channels provided opportunities for 
the community to ask questions. A CAG member advised:
“Engagement of religious leaders within the community 
would be important as many parishioners continue to seek 
advice on health and study enrolment from these leaders.”
Meetings with key stakeholders provided a venue for commu-
nity members to ask questions and gain understanding of the 
trial. One vaccinator mentioned:
“The van will just call them that ‘there is a vaccine.’ But for 
them to accept it, there should be meetings with the core 
people in the community, because they can’t ask questions 
on the van but if you meet them they will be able to ask the 
questions ‘what is happening.’”
During the community leadership and school-based meetings, 
there was a broad range of questions. The dialogue increased 
the understanding and acceptance of trial activities. (Table 1).
 4. Promoting policy interest in future rollout
The trial and community engagement activities created signif-
icant interest in national and international media. The TyVAC 
Malawi trial team conducted interviews with multiple national 
newspapers, radio programs, and television broadcasters [26, 
27], further increasing community awareness of the trial and 
raising the topic and importance of typhoid fever and TCVs. 
As Malawi and other African countries consider applying for 
Gavi funding for vaccine introduction, these key messages will 
Figure 4. Kanjipiti Times Malawi national newspaper cartoon.
Translation: “Mothers, bring your children for research study of …..whatchamacallit….Tadi..…ugghhh…..Tafiyo”
“Typhoid fever
 My brother!”
“Yes! The disease is the one mentioned by that goat like bearded man!
When I meet another person they will remind me again.”
The dialogue indicates that the local community know the message of the trial so well that they could remind and correct the village headmen’s drum-beating crier/messenger 
(who is the titular comic character of the cartoon strip, well-meaning and enthusiastic but not very well educated), when he forgot the details. Credit to Peter Nyakhuwa.
Table 1. Example List of Questions Asked During Community Meetings 
With Leaders, Parents, and Teachers
Study-specific Questions:
 •  What will happen to individuals recruited to the study but relocate?
•  Will participants receive special/extra provisions if they visit health 
centers with a medical problem?
•  Within the 28 000 children to be vaccinated, were specific age catego-
ries or groups targeted?
•  How long would the immunogenicity study be conducted, and what is 
involved?
General public health questions on typhoid transmission and control and 
sanitation and hygiene:
•  What is the safety profile of the vaccine, and what effect will it have on 
the children who receive it?
•  Has the vaccine been “certified”?
•  Will blood samples be collected in the study?
•  How will the process of randomization and blinding/unblinding be 
performed? How will the study team know which vaccine each child has 
received?
•  Why are only children aged 9 months through 12 years being vaccinated?
•  What are the main side effects of the vaccine?
•  How will the study enroll children under 5 given they are not in school?
•  What is the difference between the 2 vaccines administered?
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ensure discussions are well informed, and TCVs are on the 
national health agenda.
LESSONS
 1. The value of a combination of activities
Delivery of messages at a number of levels in the community 
from grass roots to upper ministry, ensured individuals were 
aware of the trial and informed of details.
 2. Using trusted information channels
Local leaders provided a channel to disseminate information 
and answer questions. Community trust in, and accessibility to, 
local leaders helped reassure the public.
“In one of the schools the headmistress was saying that 
some of the parents, they come to confirm – ‘we heard this 
from our kids, we had letters, is it okay to bring our kids 
here to be vaccinated?’ Because they trust the teachers, 
because they are the ones who are with their kids most of 
the times. So, they went there for confirmation.” (Frontline 
trial staff, focus group discussion [FGD])
 3. The importance of the trial team addressing misconceptions 
at enrollment
Despite community engagement activities and community 
leaders sharing information and answering questions, there 
were still misconceptions within the community. Providing in-
formation and answering questions at enrolment was important 
for addressing misconceptions and helping individuals to make 
informed decisions. Information provided at enrollment travels 
through the wider community as those messages were delivered 
back to friends and family by participants:
“One man was told that what they [MLW] are doing with 
this vaccine might affect fertility; ‘they are doing this so 
that we should not have children,’ but after explaining to 
them they said that ‘okay, now we have the right informa-
tion, we’ll bring some more children.’” (Frontline trial team 
member, FGD)
 4. Selecting appropriate channels for the context
Although a van with a loudspeaker is a relatively unsophisti-
cated approach compared to social media campaigns and other 
activities employed by trial teams in other locations, it proved 
effective in raising awareness and suited the context of low-in-
come, densely populated urban areas. Vans with loudspeakers 
are commonly used in the local community for advertising 
and other health campaigns, which meant the community was 
familiar with the approach.
Other channels proved less effective in Blantyre. Engagement 
with local chiefs is a common community engagement strategy but 
can be problematic [22]. For this trial, chiefs played a limited role 
because of challenges to hold community meetings in an urban set-
ting where people are occupied with income-generating activities:
“Chiefs here in town are very different from those in typ-
ical villages… in typical villages they really trust in chiefs 
and they can get information from the chiefs, but here in 
town it is so hard to call for a meeting. The turnup won’t 
be all that good. Most people will say; ‘we are busy, we are 
busy.’” (Frontline trial team member, FGD)
 5. The influence of wider social context on community 
enrollment
As well as influencing appropriate engagement activities, the 
social context affected trial uptake and may have encouraged 
enrolment regardless of engagement activities. In particular, 
increased vaccine uptake exists in Malawi, with trust in the ef-
fectiveness of vaccination [28]. Combined with concern and 
knowledge about the severity of typhoid, this trust in vaccina-
tion encouraged trial participation:
“Most of them know how terrible typhoid is, like in areas 
where they are doing the study when they hear that we are 
vaccinating against typhoid, so some of them have relatives 
or children who have suffered from typhoid so they said; 
‘I have to go.’”
Personal experience and an awareness of typhoid severity maybe 
the result of several years of typhoid research and engagement 
in the community prior to this trial taking place, including 
door-to-door surveys and health center recruitment [29, 30]. 
A comment from a community member on social media refer-
encing earlier MLW work highlighted:
“The [vaccine campaign] has been done after an earlier sur-
vey in which results from blood samples taken showed there 
are active patients with typhoid and they don’t know it.”
Other aspects of social context included reduced engagement 
of relatively wealthy families that prefer to attend private sec-
tor health facilities covered through health insurance schemes, 
rather than the government facilities where vaccine administra-
tion and follow-up visits occurred. This discouraged attendance 
in Zingwangwa, a wealthier area than Ndirande.
“In Zingwangwa most of the parents were not attending 
just because when we tell them that after vaccinating, when 
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the child is sick you have to go to Zingwangwa health cen-
ter. So, they say we are on MASM [insurance scheme], so 
we can’t go there…while a lot of parents at Ndirande they 
go to the health centre, they go to the government facili-
ties.” (Frontline trial staff, FGD)
DISCUSSION
The TyVAC Malawi trial team demonstrated effective methods 
for engagement in 2 densely populated urban communities in 
southern Malawi. Engagement activities proved effective in 
raising trial awareness and mobilizing community participa-
tion, as demonstrated through the current recruitment rate and 
feedback from frontline vaccine staff. We also used feedback 
that enabled appropriate engagement activity design.
A range of activities that approach different community 
stakeholders is essential to successful community engage-
ment. The social context is important to consider as traditional 
authorities have less influence than in the past, religious leader-
ship remains influential, and online social media use grows. Use 
of a van to disseminate public messages to these communities 
was an inexpensive and effective way to reach large numbers of 
people. We would recommend it in other urban areas in sub-Sa-
haran African.
Many of these lessons are based on the trial team’s perspec-
tives. A  more thorough assessment would require feedback 
from the community on TyVAC Malawi engagement activities, 
including reasons behind enrollment and people’s understand-
ings and experiences of the trial. We recognize that our engage-
ment focused primarily on informing and consulting. We did 
engage at a deeper level with some stakeholders, including part-
nerships with local and national government, for collaborative 
decision making throughout the trial process.
CONCLUSIONS
The TyVAC Malawi experience confirms the value of commu-
nity engagement on successful trial activities and enabling com-
munity awareness and recruitment. Based on our experience 
and in line with others [31, 32], we recommend:
 1. Researchers involve a wide range of stakeholders in 
discussions.
 2. Start community engagement early and continue through the 
project.
 3. Adequate resource allocation to support engagement 
activities.
 4. Use of a broad range of complementary engagement activities.
We believe sharing accounts of engagement activities, including 
benefits and lessons learned, may encourage and support other 
trial teams in undertaking effective engagement.
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